Catalyst Event
Akeso Inc (9926) · Other
From Akros SCHK HK-Korea Cosmetics Index (ASHKCOS)
6/1/2026, 12:00:00 AM
Akeso announced that its drug Ivonescimab plus chemotherapy showed a 34% reduction in the risk of death in the Phase III HARMONi-6 trial for first-line advanced squamous non-small cell lung cancer. The landmark results were presented at the ASCO 2026 Plenary Session and published in The Lancet. High importance is estimated due to the significant clinical success in a major indication, likely resulting in >10% price impact scheduled.
Korean Translation
康方生物, 자사 약물 이보시맙(Ivonescimab)과 화학요법 병용이 1차 진행성 편평 비소세포폐암(sq-NSCLC) 대상 HARMONi-6 3상 임상시험에서 사망 위험을 34% 감소시켰다고 발표함. 이 획기적인 결과는 ASCO 2026 본회의에서 발표되었고 '더 랜싯(The Lancet)'에 게재됨. 주요 적응증에서의 유의미한 임상 성공으로 10% 이상의 주가 영향이 예상됨.
Related Recent Events
Hanwha Corp (000880) · Trading Issue
Trading suspension for Hanwha Corp shares is scheduled to begin on 2026-07-30 in connection with the corporate spin-off, with trading expected to resume on 2026-08-25 upon relisting of Hanwha Corp and listing of the spun-off entity.
7/30/2026, 12:00:00 AM
Hanwha Corp (000880) · Trading Issue
Hanwha Corp confirmed a corporate spin-off creating Hanwha Machinery & Service Holdings (tentative name), separating the tech and life solutions businesses from the surviving Hanwha Corp, which will retain defense, energy, finance and related core businesses. The action also entails a scheduled trading suspension and distribution of new shares to existing holders.
7/30/2026, 12:00:00 AM
HLB Co Ltd (028300) · Other
The U.S. FDA's final decision on the New Drug Application (NDA) for the Rivoceranib and Camrelizumab combination therapy as a first-line treatment for liver cancer is expected by the PDUFA date of July 23, 2026; this major binary event is expected to have a high price impact expected
7/23/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Other
An extraordinary general meeting of shareholders to appoint a new outside director on June 30, 2026, scheduled. Low impact estimated as the appointment of an outside director is a routine administrative matter.
6/30/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
Celltrion Inc (068270) · Trading Issue
Bonus issue of 0.05 new shares per common share. The ex-rights date was June 4, 2026, with the new shares scheduled to be listed on June 30, 2026.
6/4/2026, 12:00:00 AM